Inclusion Criteria:
  -  Patients must be ≥ 3 and ≤ 18 years of age.
  -  The predicted survival period is more than 3 months.
  -  According to RECIST version 1.1, there is at least one measurable lesion.
  -  Postoperative pathological stage was group II-IV.
  -  Patients have not received radiotherapy before, and can accept chemotherapy and surgical treatment.
  -  No other anticancer therapy should be used during radiotherapy.
  -  The main organs are functioning normally, which meets the following criteria:
       1. Blood routine examination standards should be met: (no blood transfusion within 14 days) A. HB > 90 g/L; B. ANC > 1.5 * 109/L; C. PLT > 80 * 109 /L
       2. Biochemical tests should meet the following criteria:
A. BIL < 1.25 times normal upper limit (ULN); B. ALT and AST < 2.5 ULN; C. Serum Cr < 1 ULN, endogenous creatinine clearance > 50 ml/min
  -  Subjects volunteered to participate in this study, patients or legal guardians signed informed consent through patient consent, good compliance, with follow-up.
  -  Doctors believe that treatment can benefit patients.
